Incyte, Syndax Team Up On Chronic GVHD, But Some Uncertainties Remain
Data Still Early For Drug In $600m Deal
The deal could nevertheless give Incyte a competitive edge, especially with combination potential between its JAK inhibitors and Syndax’s axatilimab.
You may also be interested in...
The AUGMENT-101 study showed a strong response rate among acute leukemia patients who historically have a poor prognosis.
Public Company Edition: Prometheus brought in $500m from a follow-on offering after reporting positive mid-stage results for its TL1A inhibitor. Even Novavax, struggling to make money from its COVID-19 vaccine, raised cash in dual offerings, but its valuation dropped significantly afterward.
Japanese firm's decision to end development of entinostat in its licensed territories marks possibly final blow to development of the HDAC inhibitor in breast cancer.